A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
Status:
Completed
Trial end date:
2019-06-25
Target enrollment:
Participant gender:
Summary
This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in
which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be
evaluated in healthy adult subjects and adult subjects with indication of suspected
Nonalcoholic steatohepatitis (NASH) and liver fibrosis.